TWI896975B - 用於口服投予的包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之複合調製劑和製備彼之方法 - Google Patents

用於口服投予的包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之複合調製劑和製備彼之方法

Info

Publication number
TWI896975B
TWI896975B TW112117938A TW112117938A TWI896975B TW I896975 B TWI896975 B TW I896975B TW 112117938 A TW112117938 A TW 112117938A TW 112117938 A TW112117938 A TW 112117938A TW I896975 B TWI896975 B TW I896975B
Authority
TW
Taiwan
Prior art keywords
formulation
api
weight
relative humidity
oral
Prior art date
Application number
TW112117938A
Other languages
English (en)
Chinese (zh)
Other versions
TW202408496A (zh
Inventor
劉錫澈
李宣
溢
朴正洪
宣賢智
Original Assignee
南韓商Ｌｇ化學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南韓商Ｌｇ化學股份有限公司 filed Critical 南韓商Ｌｇ化學股份有限公司
Publication of TW202408496A publication Critical patent/TW202408496A/zh
Application granted granted Critical
Publication of TWI896975B publication Critical patent/TWI896975B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW112117938A 2020-12-01 2021-11-30 用於口服投予的包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之複合調製劑和製備彼之方法 TWI896975B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200166051 2020-12-01
KR10-2020-0166051 2020-12-01

Publications (2)

Publication Number Publication Date
TW202408496A TW202408496A (zh) 2024-03-01
TWI896975B true TWI896975B (zh) 2025-09-11

Family

ID=81854222

Family Applications (3)

Application Number Title Priority Date Filing Date
TW112117938A TWI896975B (zh) 2020-12-01 2021-11-30 用於口服投予的包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之複合調製劑和製備彼之方法
TW110144682A TWI840721B (zh) 2020-12-01 2021-11-30 用於口服投予的包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之複合調製劑和製備彼之方法
TW114111064A TW202600130A (zh) 2020-12-01 2021-11-30 唑－４－羧酸之複合調製劑和製備彼之方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW110144682A TWI840721B (zh) 2020-12-01 2021-11-30 用於口服投予的包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之複合調製劑和製備彼之方法
TW114111064A TW202600130A (zh) 2020-12-01 2021-11-30 唑－４－羧酸之複合調製劑和製備彼之方法

Country Status (15)

Country Link
US (1) US20240000751A1 (https=)
EP (1) EP4257123A4 (https=)
JP (1) JP7678106B2 (https=)
KR (1) KR20220077091A (https=)
CN (1) CN116528852A (https=)
AR (1) AR124178A1 (https=)
AU (2) AU2021390901B9 (https=)
CA (1) CA3197405A1 (https=)
CL (1) CL2023001215A1 (https=)
CO (1) CO2023008265A2 (https=)
MX (1) MX2023005459A (https=)
PE (1) PE20240222A1 (https=)
TW (3) TWI896975B (https=)
WO (1) WO2022119269A1 (https=)
ZA (1) ZA202305156B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240242A1 (es) * 2021-06-15 2024-02-16 Lg Chemical Ltd Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05000862A (es) * 2002-07-31 2005-04-19 Pharmacia Corp Forma de dosificacion farmaceutica capaz de mantener un perfil de disolucion estable tras el almacenamiento.
DE602006014607D1 (de) * 2005-01-21 2010-07-15 Teva Pharma Stabile pharmazeutische Zusammensetzungen von Zonisamide und Verfahren zur deren Herstellung
JP5330989B2 (ja) * 2007-04-11 2013-10-30 キッセイ薬品工業株式会社 （アザ）インドール誘導体及びその医薬用途
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
WO2020109319A1 (en) * 2018-11-27 2020-06-04 Zaklady Farmaceutyczne Polpharma S.A Pharmaceutical composition comprising ramipril and indapamide
US20240000750A1 (en) * 2020-11-04 2024-01-04 Lg Chem, Ltd. Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same
PE20230850A1 (es) * 2020-12-01 2023-05-23 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
TWI903066B (zh) * 2021-04-16 2025-11-01 南韓商Ｌｇ化學股份有限公司 包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之口服用複合調配物

Also Published As

Publication number Publication date
CL2023001215A1 (es) 2023-12-15
CA3197405A1 (en) 2022-06-09
WO2022119269A1 (ko) 2022-06-09
JP7678106B2 (ja) 2025-05-15
EP4257123A1 (en) 2023-10-11
AU2021390901B9 (en) 2024-11-21
KR20220077091A (ko) 2022-06-08
AU2024227367A1 (en) 2024-10-31
JP2023551712A (ja) 2023-12-12
ZA202305156B (en) 2024-09-25
AU2021390901A1 (en) 2023-06-08
TW202600130A (zh) 2026-01-01
AU2021390901B2 (en) 2024-11-07
TW202408496A (zh) 2024-03-01
TWI840721B (zh) 2024-05-01
PE20240222A1 (es) 2024-02-16
AU2021390901A9 (en) 2024-05-23
US20240000751A1 (en) 2024-01-04
CN116528852A (zh) 2023-08-01
EP4257123A4 (en) 2024-05-08
AR124178A1 (es) 2023-02-22
CO2023008265A2 (es) 2023-06-30
TW202228679A (zh) 2022-08-01
MX2023005459A (es) 2023-05-23

Similar Documents

Publication Publication Date Title
TWI896975B (zh) 用於口服投予的包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之複合調製劑和製備彼之方法
JP7639173B2 (ja) １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む経口用製剤
JP2025039725A (ja) １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む経口用製剤、およびその製造方法
JP2005187464A (ja) 固形製剤およびその製造方法
JP2019526641A (ja) テソフェンシン組成物
HK40095726A (zh) 含有1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的稳定的口服制剂
EP4342458A1 (en) Oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
HK40095918A (zh) 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的口服制剂及其制备方法
WO2025162195A1 (zh) 包衣复方片剂
HK40102233A (zh) 含有1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的口服制剂
JP2024107445A (ja) フェブキソスタット製剤
EA049988B1 (ru) Лекарственная форма для перорального применения, содержащая 1-(3-циано-1-изопропил-индол-5-ил)пиразол-4-карбоновую кислоту
JP2021165266A (ja) ビルダグリプチン錠剤およびその製造方法
TW201607568A (zh) 包含１－［６－（嗎啉－４－基）嘧啶－４－基］－４－（１ｈ－１，２，３－三唑－１－基）－１ｈ－吡唑－５－醇鈉之醫藥劑型
WO2007113371A1 (en) Pharmaceutical composition and preparation method thereof